Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RICHARDSON-VICKS TAKEOVER RUMORS FUEL FRENZIED TRADING, PUSHES STOCK UP

Executive Summary

Rich-Vicks (up 3-3/8 to 40) was the biggest point gainer on the "F-D-C" Index during the week ended Sept. 6, after rumors emerged on the "Street" late last week concerning a buyout of the company -- by either American Cyanamid or Unilever. Despite Cyanamid's denial that it had made an offer, Rich-Vicks stock was traded heavily, with volume reaching nearly 675,000 shares on Friday. The company refused to comment on the unusual activity. Investors reacted favorably to Avon's (up 2-1/8 to 24) announcement that it would sell its Mallinckrodt unit and use the proceeds, which could amount to $500 mil., to buy back up to 25% of its outstanding common stock (see related story). Syntex (up 2-1/2 to 63) showed a strong northward move after the company announced that its fourth quarter earnings leaped 65%. Overall, health-related issues did not fare well, as the Composite dropped a little more than a point over the week, compared to a similar rise for the Dow average, which finished at 1335. Losers out numbered gainers on the lndex 30 to 18, with three issues remaining unchanged. Chain stocks were the biggest component losers, with only two of 10 companies showing gains. American Stores (down 2 to 56-1/8) declined after announcing flat second quarter earnings. Chart omitted.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS008908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel